# 18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

> **NCT00654745** · PHASE4 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 207 (actual)

## Conditions studied

- Type 2 Diabetes
- Hypertension

## Interventions

- **DRUG:** Amlodipine
- **DRUG:** amlodipine / olmesartan medoxomil combination
- **DRUG:** Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00654745
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-04
- **Final completion:** 2009-06
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2010-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654745, "18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00654745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*